Candel Therapeutics Newsroom

Candel Therapeutics Analyst Ratings

BenzingaNov 13, 2023 08:46 ET

Candel Therapeutics' Promising Clinical Progress and Financial Stability: A Buy Recommendation

TipRanksNov 13, 2023 06:37 ET

Promising Potential of CAN-2409 Elevates Candel Therapeutics to a Buy Rating: A Detailed Analysis

TipRanksSep 26, 2023 10:15 ET

H.C. Wainwright Sticks to Their Buy Rating for Candel Therapeutics (CADL)

TipRanksAug 24, 2023 10:35 ET

Candel Therapeutics (CADL) Receives a Buy From H.C. Wainwright

TipRanksMay 22, 2023 06:25 ET

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target

BenzingaMay 22, 2023 06:16 ET

BMO Capital Maintains Outperform on Candel Therapeutics, Lowers Price Target to $3

BenzingaMay 15, 2023 08:31 ET

Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $7

BenzingaMar 31, 2023 08:57 ET

Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating

MT NewswiresMar 31, 2023 08:48 ET

UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating

MT NewswiresDec 9, 2022 10:03 ET

H.C. Wainwright Keeps Their Buy Rating on Candel Therapeutics (CADL)

TipRanksDec 8, 2022 08:35 ET

Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating

MT NewswiresDec 8, 2022 05:57 ET

BMO Capital Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

TipRanksDec 7, 2022 10:10 ET

Candel Therapeutics Analyst Ratings

Benzinga Analyst RatingsDec 7, 2022 07:57 ET

Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $8

Benzinga Real-time NewsDec 7, 2022 07:57 ET

Candel Therapeutics Analyst Ratings

Benzinga Analyst RatingsDec 2, 2022 06:32 ET

HC Wainwright & Co. Initiates Coverage On Candel Therapeutics With Buy Rating, Announces Price Target of $11

Benzinga Real-time NewsDec 2, 2022 06:32 ET